Mizuho raises Amylyx target to $30, keeps Outperform
Mizuho analyst Graig Suvannavejh raised Amylyx's price target to $30 from $24 and kept an Outperform rating after the Q2 report, citing updated launch pricing assumptions for avexitide.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.